Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_assertion type Assertion NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_head.
- NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_assertion description "[After 6 d of treatment with 50 nM geldanamycin, the percent inhibition of growth was 29.4% in TPC-1, 97.5% in FTC-133, 96.7% in FTC-236, 10.8% in FTC-238, 70.9% in XTC-1, and 45.5% in ARO cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_provenance.
- NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_assertion evidence source_evidence_literature NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_provenance.
- NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_assertion SIO_000772 12843186 NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_provenance.
- NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_assertion wasDerivedFrom befree-20140225 NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_provenance.
- NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_assertion wasGeneratedBy ECO_0000203 NP768864.RAB-6lnrVZDzwC1TLKIv1SJM08P5fiT5xc1xMfAFUoxEY130_provenance.